Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1997
Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients
C H Takimoto, W Dahut, M T Marino, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 23, 2016
Utility of <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy
Frank I Lin, E M Gonzalez, S Kummar, et al.
Scientific Reports
|
August 12, 2017
Epitaxial thin films of pyrochlore iridate Bi<sub>2+x</sub>Ir<sub>2-y</sub>O<sub>7-δ</sub>: structure, defects and transport properties
W C Yang, Y T Xie, W K Zhu, et al.
Cancer Chemotherapy and Pharmacology
|
March 28, 2001
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion
J L Grem, M Quinn, A S Ismail, et al.
Magnetic Resonance in Medicine
|
March 26, 2009
Imaging considerations for in vivo 13C metabolic mapping using hyperpolarized 13C-pyruvate
Y-F Yen, S J Kohler, A P Chen, et al.
Cancer Chemotherapy and Pharmacology
|
October 11, 2001
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients
R R Thomas, W Dahut, N Harold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2000
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
C H Takimoto, G Morrison, N Harold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]
K L Jhaveri, X V Wang, V Makker, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1997
Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients
C H Takimoto, W Dahut, M T Marino, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
November 23, 2016
Utility of <sup>18</sup>F-fluoroestradiol (<sup>18</sup>F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy
Frank I Lin, E M Gonzalez, S Kummar, et al.
Scientific Reports
|
August 12, 2017
Epitaxial thin films of pyrochlore iridate Bi<sub>2+x</sub>Ir<sub>2-y</sub>O<sub>7-δ</sub>: structure, defects and transport properties
W C Yang, Y T Xie, W K Zhu, et al.
Cancer Chemotherapy and Pharmacology
|
March 28, 2001
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion
J L Grem, M Quinn, A S Ismail, et al.
Magnetic Resonance in Medicine
|
March 26, 2009
Imaging considerations for in vivo 13C metabolic mapping using hyperpolarized 13C-pyruvate
Y-F Yen, S J Kohler, A P Chen, et al.
Cancer Chemotherapy and Pharmacology
|
October 11, 2001
A phase I and pharmacologic study of 9-aminocamptothecin administered as a 120-h infusion weekly to adult cancer patients
R R Thomas, W Dahut, N Harold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2000
Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients
C H Takimoto, G Morrison, N Harold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]
K L Jhaveri, X V Wang, V Makker, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Page
of 4